J&J reportedly in talks to buy Protagonist (JNJ:NYSE)

Core Viewpoint - Protagonist Therapeutics (NASDAQ:PTGX) experienced a ~30% increase in trading after reports emerged that Johnson & Johnson (NYSE:JNJ) is in discussions to acquire the company [2] Company Summary - Protagonist Therapeutics is a biotech firm that specializes in peptide-based therapeutics [2] - The potential acquisition by Johnson & Johnson indicates strategic interest in Protagonist's technology and product pipeline [2] Industry Context - The news reflects ongoing consolidation trends in the biotech industry, where larger firms seek to enhance their portfolios through acquisitions [2] - The interest from a major player like Johnson & Johnson highlights the value and potential of peptide-based therapeutics in the current market [2]